Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan.

Scientific reports - 30 Mar 2023

Matsumoto Hiromi, Kobayashi Nobuaki, Shinoda Satoru, Goto Atsushi, Kaneko Ayami, Fukuda Nobuhiko, Kamimaki Chisato, Kubo Sousuke, Watanabe Keisuke, Horita Nobuyuki, Hara Yu, Ishikawa Yoshihiro, Kaneko Takeshi

Abstract excerpt

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are extensively used in the treatment of non-small cell lung cancer (NSCLC); hence, equal access to them is important. Therefore, this study aimed to identify regional differences in the prescription of EGFR-TKIs and the factors contributing to these differences. In this ecological study, we collected data using the National Database Open...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36997606
DOI: 10.1038/s41598-023-31856-6
PMCID: PMC10063675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan.PMID 36997606Read ↗

Changes in survival of patients with non-small cell lung cancer in Japan: An interrupted time series study.Semantic proximity Read ↗

Public assistance and survival equality in patients with EGFR mutation-positive lung cancer.Semantic proximity Read ↗

National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China.Semantic proximity Read ↗

Medical Insurance Payment Schemes and Patient Medical Expenses: A Cross- Sectional Study of Lung Cancer Patients in Urban ChinaSemantic proximity Read ↗

Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area.Semantic proximity Read ↗

Does pathologic type shape the hospitalization costs of advanced non- small cell lung cancer patients? A multicenter real-world data studySemantic proximity Read ↗

Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study.Semantic proximity Read ↗

Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study.Semantic proximity Read ↗

Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.Semantic proximity Read ↗

Patients' Preferences for Attributes of Molecular Targeting Therapies for Advanced Non-Small Cell Lung Cancer with EGFR Mutations in Japan-A Discrete-Choice Experiment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.